x

Posted 04 May, 2023

BRISTOL MYERS SQUIBB CO appointed Christopher Boerner, Ph.D. as new CEO

NYSE:BMY appointed new Chief Executive Officer Christopher Boerner, Ph.D. in a 8-K filed on 04 May, 2023.


  On April 26, 2023, Bristol Myers Squibb Company (the "Company") announced that the Board of Directors of the Company ("Board") appointed Christopher Boerner, Ph.D., to serve as the Company's Chief Operating Officer, effective April 26, 2023, and as the Chief Executive Officer, effective November 1, 2023.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of BRISTOL MYERS SQUIBB CO
Health Care/Life Sciences • Pharmaceuticals
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Market Cap
$121B
View Company Details
BRISTOL MYERS SQUIBB CO by TradingView
Relevant filing section
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


(d) On April 26, 2023, Bristol Myers Squibb Company (the "Company") announced that the Board of Directors of the Company ("Board") appointed Christopher Boerner, Ph.D., to serve as the Company's Chief Operating Officer, effective April 26, 2023, and as the Chief Executive Officer, effective November 1, 2023. On May 2, 2023, the Board elected Dr. Boerner, to serve as a member of the Board, effective May 2, 2023, after the Annual Meeting. The size of the Board was increased to twelve, effective May 2, 2023, in connection with the election of Dr. Boerner.


Dr. Boerner, 52, has worked for the Company since 2015 in roles of increasing seniority. He served as the Company's Executive Vice President and Chief Commercialization Officer from August 2018 to April 2023. Dr. Boerner previously served as Head, International Markets from October 2017 to July 2018, and as President and Head of U.S. Commercial from February 2015 to September 2017.


Due to his employment with the Company, the Board has determined that Dr. Boerner is not independent under the New York Stock Exchange Listing Standards or the independence standards adopted by the Board. Dr. Boerner will not serve on any committees of the Board.


Dr. Boerner was not selected as a director pursuant to any arrangement or understanding between him and any other person. There are no related party transactions between the Company and Dr. Boerner and there are no family relationships between Dr. Boerner and any director or executive officer of the Company.


Dr. Boerner will not be compensated for his service as a director of the Company.